Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge

被引:56
作者
Breathnach, CC
Clark, HJ
Clark, RC
Olsen, CW
Townsend, HGG
Lunn, DP [1 ]
机构
[1] Colorado State Univ, Dept Clin Sci, Coll Vet Med & Biomed Sci, Ft Collins, CO 80523 USA
[2] Univ Wisconsin, Dept Med Sci, Sch Vet Med, Madison, WI 53706 USA
[3] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA
[4] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
关键词
horses; influenza virus; vaccination; haemaggluttinin; nucleoprotein;
D O I
10.1016/j.vaccine.2005.08.091
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Two novel recombinant strains of modified vaccinia Ankara (rMVA) for the vaccination of horses against equine influenza virus were developed, and preliminary evidence of their immunogenicity in ponies was demonstrated [Breathnach CC, Rudersdorf R, Lunn DP. Use of recombinant modified vaccinia Ankara vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004:98; 127-36]. The present study assessed the protective efficacy of these rMVA strains in ponies, examined the advantage of combining rMVA vaccination with a DNA priming dose, and investigated the protection resulting from equine influenza nucleoprotein (NP) versus haemagglutinin (HA) vaccination. Twenty yearling ponies, seronegative for equine influenza virus, were divided into four groups of five. Group I and Group 2 ponies were vaccinated using a DNA prime-rMVA boost vaccination regimen, with HA- or NP-expressing vectors, respectively. Group 3 ponies were vaccinated with rMVA-HA only. Group 4 ponies served as unvaccinated controls. Vaccines were administered on days 0, 42 and 70, and all ponies were challenge infected with influenza virus on day 100. Antigen-specific antibody and cellular immune responses to each vaccination regimen were monitored throughout the experiment. Both groups of HA-vaccinated ponies were significantly protected from clinical disease following challenge infection, demonstrating the efficacy of rMVA vaccination with or without a DNA prime. NP-vaccination provided more limited protection from clinical disease. The protective post-vaccinal immune responses were characterized by antigen-specific IgGa, IgGb and IgA antibodies which were induced both in serum and in nasal secretions. Virus-specific lymphoproliferative and IFN-gamma mRNA responses were also elicited by each vaccination regimen. These data demonstrate that vaccination of horses with rMVA alone, or as part of a prime-boost regimen, is an effective means of inducing protective immunity to influenza virus infection, and also indicate that NP-specific immune responses can contribute to protection of horses. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1180 / 1190
页数:11
相关论文
共 50 条
  • [1] Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
    Allen, TM
    Vogel, TU
    Fuller, DH
    Mothé, BR
    Steffen, S
    Boyson, JE
    Shipley, T
    Fuller, J
    Hanke, T
    Sette, A
    Altman, JD
    Moss, B
    McMichael, AJ
    Watkins, DI
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (09) : 4968 - 4978
  • [2] Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine
    Belshe, RB
    Gruber, WC
    Mendelman, PM
    Mehta, HB
    Mahmood, K
    Reisinger, K
    Treanor, J
    Zangwill, Z
    Hayden, FG
    Bernstein, DI
    Kotloff, K
    King, J
    Piedra, PA
    Block, SL
    Yan, LH
    Wolff, M
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) : 1133 - 1137
  • [3] BINNS M, 1999, P 8 INT C EQ INF DIS, P477
  • [4] Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes
    Boon, ACM
    de Mutsert, G
    van Baarle, D
    Smith, DJ
    Lapedes, AS
    Fouchier, RAM
    Sintnicolaas, K
    Osterhaus, ADME
    Rimmelzwaan, GF
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (04) : 2453 - 2460
  • [5] Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination
    Breathnach, CC
    Rudersdorf, R
    Lunn, DP
    [J]. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2004, 98 (3-4) : 127 - 136
  • [6] The mucosal humoral immune response of the horse to infective challenge and vaccination with Equine herpesvirus-1 antigens
    Breathnach, CC
    Yeargan, MR
    Sheoran, AS
    Allen, GP
    [J]. EQUINE VETERINARY JOURNAL, 2001, 33 (07) : 651 - 657
  • [7] Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein
    Chen, Z
    Yoshikawa, T
    Kadowaki, S
    Hagiwara, Y
    Matsuo, K
    Asanuma, H
    Aizawa, C
    Kurata, T
    Tamura, S
    [J]. JOURNAL OF GENERAL VIROLOGY, 1999, 80 : 2559 - 2564
  • [8] Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8+ T-cell memory
    Christensen, JP
    Doherty, PC
    Branum, KC
    Riberdy, JM
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (24) : 11690 - 11696
  • [9] Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara:: enhanced CD8+T cell immunogenicity and protective efficacy in the influenza and malaria models
    Dégano, P
    Schneider, J
    Hannan, CM
    Gilbert, SC
    Hill, AVS
    [J]. VACCINE, 1999, 18 (7-8) : 623 - 632
  • [10] Fu TM, 1999, J IMMUNOL, V162, P4163